Oncogenic KRAS-MAPK signaling sustains a CD73 dependent therapeutic vulnerability in pancreatic cancer
Khadija Shahab Turabi, Urvinder Kaur Sardarni, Katherine E. Ankenbauer…·Jennifer M. Bailey
This study shows that combining CD73 and RAS(ON) inhibition reduces tumor growth and immune suppression in pancreatic cancer by targeting KRAS-MAPK driven CD73 signaling.